专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20230293634A1 ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS 审中-公开
公开(公告)号：US20230293634A1
公开(公告)日：2023-09-21
申请号：US18156015
申请日：2023-01-18
申请人： Celgene Corporation , Washington University
发明人： Victoria Sung , Randall Stevens , William Smith , Victor Schorr Sloan , Keith Hruska , Yifu Fang
IPC分类号： A61K38/17
CPC分类号： A61K38/1796 , A61K38/179
摘要： Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

2. 发明授权

US10195249B2 Activin-ActRII antagonists and uses for treating bone and other disorders 有权
公开(公告)号：US10195249B2
公开(公告)日：2019-02-05
申请号：US14438146
申请日：2013-11-01
申请人： CELGENE CORPORATION , Washington University
发明人： Victoria Sung , Randall Stevens , William Smith , Victor Schorr Sloan , Keith Hruska , Yifu Fang
IPC分类号： A61K38/16 , A61K38/17
摘要： Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

3. 发明授权

US11813308B2 Treatment of cardiovascular disease using ActRII ligand traps 有权
公开(公告)号：US11813308B2
公开(公告)日：2023-11-14
申请号：US15517782
申请日：2015-10-08
申请人： CELGENE CORPORATION , WASHINGTON UNIVERSITY
发明人： Keith Hruska , Yifu Fang , William Smith , Nianhang Chen
IPC分类号： A61K38/17 , A61K38/00 , C07K14/71 , A61P9/10 , A61P9/00 , A61P19/10
CPC分类号： A61K38/179 , A61P9/00 , A61P9/10 , A61P19/10 , C07K14/71 , A61K38/00 , C07K2319/30
摘要： Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor. Provided herein are methods of bone resorption in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), c-terminal telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.

4. 发明申请

US20150283209A1 ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS 审中-公开
标题翻译： ACTIVIN-ACTRII ANTAGONISTS和用于治疗骨骼和其他疾病的用途
公开(公告)号：US20150283209A1
公开(公告)日：2015-10-08
申请号：US14438146
申请日：2013-11-01
申请人： Victor Schorr SLOAN , Keith HRUSKA , Yifu FANG , CELGENE CORPORATION , WASHINGTON UNIVERSITY
发明人： Victoria Sung , Randall Stevens , William Smith , Victor Schorr Sloan , Keith Hruska , Yifu Fang
IPC分类号： A61K38/17
CPC分类号： A61K38/1796 , A61K38/179
摘要： Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.
摘要翻译：本文提供了用于治疗与肾脏疾病相关的骨病症的方法，其中所述方法包括向需要治疗的受试者施用Activin-ActRIIA抑制剂。本文还提供了用于治疗低周转性骨疾病的方法和组合物，其中所述方法包括向需要治疗的受试者施用Activin-ActRIIA抑制剂。本文还提供了用于治疗与肾脏疾病相关的骨疾病的组合物和用于治疗低周转性骨病和血管钙化的组合物。

5. 发明申请

US20190262423A1 ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS 审中-公开
公开(公告)号：US20190262423A1
公开(公告)日：2019-08-29
申请号：US16238351
申请日：2019-01-02
申请人： CELGENE CORPORATION , Washington University
发明人： Victoria Sung , Randall Stevens , William Smith , Victor Schorr Sloan , Keith Hruska , Yifu Fang
IPC分类号： A61K38/17
摘要： Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-Act-RIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

6. 发明申请

US20170304397A1 TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS 审中-公开
公开(公告)号：US20170304397A1
公开(公告)日：2017-10-26
申请号：US15517782
申请日：2015-10-08
申请人： CELGENE CORPORATION , WASHINGTON UNIVERSITY
发明人： Keith Hruska , Yifu Fang , William Smith , Nianhang Chen
IPC分类号： A61K38/17 , C07K14/71 , A61K38/00
CPC分类号： A61K38/179 , A61K38/00 , A61P9/00 , A61P9/10 , A61P19/10 , C07K14/71 , C07K2319/30
摘要： Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor. Provided herein are methods of bone resorption in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), c-terminal telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式